Featured Story | By Max Bayer Marinus is selling off a priority review voucher to Novo Nordisk for $110 million. The company plans to use the additional funds to pay for two ongoing phase 3 trials and the launch of its new seizure med, Ztalmy. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor After keeping investors waiting for months, ContraFect has revealed its phase 3 clinical trial has failed an interim futility analysis. The inability of the direct lytic agent to beat placebo triggered the stoppage of the study and the cratering of the biotech’s share price. read more By Nick Paul Taylor First the setback, then the cuts. CytomX Therapeutics became the latest biotech to follow the rhythm of the industry late Wednesday when it set out plans to reduce its headcount by 40% to extend its cash runway after its lead candidate failed to meet the bar for moving into phase 3. read more Sponsored by: Lonza AG Advance your AAV-based therapeutics by leveraging Lonza expertise, using the same tools and technologies used for our platform processes. Balance risk and speed, while maintaining high AAV productivity read more By Max Bayer Manifold Bio is adding $40 million in series A funds to help finance its protein barcoding technology intended to rapidly speed up preclinical development. The company, founded in part by famed geneticist George Church, has already started to launch internal oncology programs. read more Sponsored by: Parexel The rise of clinical trial complexity has been well-documented but the impact on logistics is not well understood. Here, we look at decentralized trials, patient experience and the role of logistics. read more By Annalee Armstrong Summit Therapeutics’ troubled C. difficile medicine may have a path forward after the FDA cleared a section of trail—however, it’s going to be a steep climb. read more By Angus Liu New PD-1 cancer immunotherapies have had a hard time reaching the U.S. lately. For Novartis and BeiGene’s China-approved contender, the roadblock comes in the form of COVID-related travel restrictions. read more By Gabrielle Masson Researchers at the National Institutes of Health are moving closer to the holy grail of the vaccine world: a universal flu shot. read more By Zoey Becker Like many other businesses around the world, the biopharma industry has had a rough go of it in the first half of 2022. And drugmakers' share price changes largely reflected that tough environment, Evaluate Vantage reports. read more By Angus Liu In search of mechanisms driving increased itch sensation after scratching, scientists at Washington University School of Medicine have identified a “miswiring” of nerve fibers onto touch-sensing skin cells. read more By Fraiser Kansteiner Late Wednesday, the FDA gave the all-clear to Novavax’s protein-based shot, teeing up the nation’s fourth pandemic prophylactic behind those from Pfizer-BioNTech, Moderna and Johnson & Johnson. read more By Andrea Park A new partnership between Twist Bioscience and DNAnexus seeks to weave together two crucial pieces of the genomic sequencing puzzle. read more By Fraiser Kansteiner Teva's skinny label lawsuit, which hinges on a copycat version of GSK’s heart med Coreg, could have “enormous” implications for a common practice among generic drug makers, the company argues. That could in turn sow “competition-killing uncertainty” that the U.S. healthcare system “cannot sustain,” Teva said in a petition made public on Wednesday. read more Resources Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Lumanity Check out our 22 on-demand panels, featuring 100+ speakers. Tap into discussions of scientific progress in oncology around development, regulatory, clinical, commercial and investment perspectives. Sponsored by: Cognizant Explore how Cognizant SIP helped Roche streamline its global feasibility process. Sponsored by: Blue Matter Consulting For an emerging biopharma company, Europe can be very attractive. But it can also be complex and confusing. This e-book covers the 12 most common pitfalls for companies entering European markets for the first time, offering guidance to help growing companies avoid them and succeed. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Decentralized Clinical Trials Forum July 26, 2022 | Free Virtual Event Fierce Biotech Summit September 19-20, 2022 | Boston, MA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Health Payer Forum October 12, 2022 | Free Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Virtual Event Clinical Quality Oversight Forum: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia PA | Presented by: Fierce Pharma Decentralized Clinical Trials Summit: Part of the Fierce Clinical Collective Oct 24-26, 2022 | Philadelphia, PA | Presented by: Fierce Pharma Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Diversity, Equity & Inclusion Forum November 15-16, 2022 | Free Virtual Event Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual Fierce Clinical Trial Billing & Research Compliance Summit February 2023 | Location TBD Fierce BD&L Summit for Life Sciences March 14-15, 2023 | San Francisco, CA | 
